CERENOVUS Reveals Positive Outcomes with Thrombectomy in Global Registry Studying Stroke-Inducing Blood Clots

EXCELLENT study demonstrates real-world benefits of CERENOVUS' EMBOTRAP™ Revascularization Devices on clinical outcomes and first pass reperfusion IRVINE, Calif., Nov. 18, 2022 /PRNewswire/ -- CERENOVUS, Inc., part of Johnson & Johnson MedTech*, today announced positive primary outcomes...

Click to view original post